RAGE Biotech
The spin-out company, RAGE Biotech, will develop novel therapies designed to help patients with chronic inflammatory lung diseases such as severe asthma, cystic fibrosis and chronic obstructive pulmonary disease (COPD), supported by investment from IP Group, Monash University (Monash) and the University of Western Australia (UWA).
Globally, COPD is the fourth leading cause of mortality and morbidity, with chronic inflammation being a key feature and driver of disease progression in COPD, cystic fibrosis and severe asthma.
The breakthrough discoveries were led by endocrinology expert Professor Merlin Thomas of the Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, in collaboration with Professor Kevin Pfleger of UWA and the Harry Perkins Institute of Medical Research and Professor Steve Wilton of Murdoch University.